Verastem (VSTM) News Today $5.60 -0.28 (-4.76%) Closing price 04:00 PM EasternExtended Trading$5.84 +0.24 (+4.20%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Verastem, Inc. (NASDAQ:VSTM) Receives $13.63 Average PT from AnalystsJune 6, 2025 | americanbankingnews.comVerastem reports promising cancer drug trial resultsJune 4, 2025 | investing.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 4, 2025 | businesswire.comVerastem’s Promising Clinical Advances and Strategic Developments Justify Buy RatingJune 3, 2025 | tipranks.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from BrokeragesVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given an average recommendation of "Buy" by the nine brokerages that are presently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that hJune 3, 2025 | marketbeat.comVerastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns BullishJune 2, 2025 | msn.comVerastem Announces Strategic Plans in Investor WebcastJune 2, 2025 | tipranks.comWhat's Going On With Verastem Oncology Stock On Monday?June 2, 2025 | benzinga.comVerastem, Inc. (NASDAQ:VSTM) Short Interest UpdateVerastem, Inc. (NASDAQ:VSTM - Get Free Report) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 13,280,000 shares, a growth of 42.5% from the April 30th total of 9,320,000 shares. Currently, 27.4% of the company's stock are sold short. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is currently 10.0 days.June 2, 2025 | marketbeat.comVerastem Announces Promising Phase 1 Study ResultsJune 2, 2025 | tipranks.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 2, 2025 | businesswire.comInvestors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)Verastem, Inc. (NASDAQ:VSTM - Get Free Report) was the target of some unusual options trading activity on Friday. Stock investors acquired 2,156 call options on the company. This represents an increase of 275% compared to the average volume of 575 call options.May 31, 2025 | marketbeat.comVerastem Oncology to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNorthern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)Northern Trust Corp grew its position in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 18.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 339,264 shares of the biopharmaceutical company's stock after purchasing an aMay 28, 2025 | marketbeat.com723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LPWoodline Partners LP bought a new position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 723,806 shares of the biopharmaceutical company's stockMay 27, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)BNP Paribas Financial Markets purchased a new stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 74,904 shares of the biopharmaceutical company's stock, valued aMay 27, 2025 | marketbeat.comVerastem’s SWOT analysis: biotech firm’s stock poised for growth amid challengesMay 23, 2025 | investing.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...May 23, 2025 | finance.yahoo.comVerastem announces positive Phase 1/2 safety and efficacy results in PDACMay 23, 2025 | finance.yahoo.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal AdenocarcinomaMay 22, 2025 | businesswire.comSoleus Capital Management L.P. Reduces Stock Position in Verastem, Inc. (NASDAQ:VSTM)Soleus Capital Management L.P. cut its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,184,026 shares of the biopharmaceutical company's stock after selling 643,May 21, 2025 | marketbeat.comInsider Selling: Verastem, Inc. (NASDAQ:VSTM) CFO Sells 11,143 Shares of StockMay 21, 2025 | insidertrades.comTempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination TreatmentMay 20, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Shares Sold by Stonepine Capital Management LLCStonepine Capital Management LLC lowered its position in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 33.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 870,000 shares of the biopharmaceutical company's stock after selling 440,287 shares duriMay 20, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Takes $187,000 Position in Verastem, Inc. (NASDAQ:VSTM)Schonfeld Strategic Advisors LLC acquired a new position in Verastem, Inc. (NASDAQ:VSTM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 36,180 shares of the biopharmaceutical company's stock, valued at approximately $187,000.May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 177,855 Shares of Verastem, Inc. (NASDAQ:VSTM)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 41.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 608,524 shMay 15, 2025 | marketbeat.comVerastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business UpdatesMay 13, 2025 | businesswire.comVerastem (NASDAQ:VSTM) Given New $14.00 Price Target at HC WainwrightHC Wainwright raised their price objective on shares of Verastem from $10.00 to $14.00 and gave the company a "buy" rating in a research note on Friday.May 11, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by BrokeragesVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given a consensus recommendation of "Buy" by the ten research firms that are presently covering the company, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price target aMay 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New $20.40 Million Investment in Verastem, Inc. (NASDAQ:VSTM)Balyasny Asset Management L.P. purchased a new stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,945,927 shares of the biopharmaceutical companMay 10, 2025 | marketbeat.comVerastem Oncology Cancer Drug Combination Gets FDA ApprovalMay 9, 2025 | marketwatch.comVerastem (VSTM) Sees Price Target Increase and FDA Approval Boost | VSTM Stock NewsMay 9, 2025 | gurufocus.comUS FDA approves Verastem's ovarian cancer therapyMay 9, 2025 | msn.comVerastem Ovarian-Cancer Drug Combination Gets FDA Approval -- UpdateMay 8, 2025 | marketwatch.comVerastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s PleasedMay 8, 2025 | msn.comFDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian CancerMay 8, 2025 | benzinga.comVerastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC TherapyMay 8, 2025 | tipranks.comFDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian CancerMay 8, 2025 | businesswire.comU.S. FDA approves Verastem's cancer therapyMay 8, 2025 | reuters.comSusquehanna Fundamental Investments LLC Buys New Shares in Verastem, Inc. (NASDAQ:VSTM)Susquehanna Fundamental Investments LLC purchased a new position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 63,411 shares ofMay 7, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Holdings Boosted by BVF Inc. ILBVF Inc. IL grew its holdings in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 24.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,100,468 shares of the biopharmaceutical company's stock after pMay 6, 2025 | marketbeat.comB. Riley Has Pessimistic Outlook of Verastem Q2 EarningsVerastem, Inc. (NASDAQ:VSTM - Free Report) - Analysts at B. Riley dropped their Q2 2025 earnings estimates for Verastem in a report issued on Monday, April 28th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will post earnings of ($0.56) per share for the quarter, downMay 3, 2025 | marketbeat.comVerastem (VSTM) to Release Earnings on ThursdayVerastem (NASDAQ:VSTM) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-verastem-inc-stock/)May 3, 2025 | marketbeat.comB. Riley Has Optimistic Outlook of Verastem FY2029 EarningsVerastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at B. Riley increased their FY2029 EPS estimates for Verastem in a note issued to investors on Monday, April 28th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings per share of $May 2, 2025 | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesMay 2, 2025 | finance.yahoo.comVerastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 948,790 shares of the biopharmaceutical company's stock after buying aApril 28, 2025 | marketbeat.comMarshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)Marshall Wace LLP acquired a new stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 793,641 shares of the biopharmaceutical company's stock, valued at approximately $April 27, 2025 | marketbeat.comVerastem Oncology Announces $75 million Private Placement | VSTM Stock NewsApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | finance.yahoo.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.930.88▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼14▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MannKind News Dynavax Technologies News Novavax News OPKO Health News Geron News Regulus Therapeutics News Zenas Biopharma News Myriad Genetics News Rigel Pharmaceuticals News Emergent BioSolutions News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
